Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...

Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME) Oculis completes patient recruitment for stage 1 of Phase 3 DIAMOND study evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME) Oculis has completed enrollment for stage 1...